glp 1 hepatic steatosis Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? Current Status of Glucagon-like Peptide-1

Any references to overlapping pathway activity are included solely for scientific context and do not imply that the blend is intended to heal, regenerate, or treat any condition

Some analyses show 12-58% of products contain contamination, 30% have incorrect amino acid sequences, 65% exceed endotoxin safety thresholds, and 20% are mislabeled entirely

Its estimated as much as 40% of the weight loss is lean muscle mass, but when weight is put back on its almost all fat, so in fact they are actually worse off than when they started

Kaufmans fear is that both trials will fail because too many patients will suffer side effects and withdraw, and the drug will be forever lost to vast majority of long-COVID patients